Terfenadine
As of the edition of 20 October 2026, Terfenadine is a small molecule: withdrawn from the market in 1997; acts on HRH1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Withdrawn from market, 1997
- Kind
- Small molecule
- Withdrawn from market
- 1 January 1997 (in some regions)
- Registered trials
- 26, 7 stopped early
- Disease areas
- Infections; Immune system; Digestive system; Nervous system; Cancer; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HRH1 | Histamine H1 receptor | P35367 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 5 | 2 | 2 | 1 |
| Phase 1 | 4 | 2 | 1 | 1 |
| Phase 2 | 10 | 2 | 3 | 4 |
| Phase 3 | 6 | 3 | 2 | 1 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 26 |